AzTrials
AzTrials

Aortic StenosisTAVI-QoLNCT07798713

Quality of Life After Transcatheter Aortic Valve Implantation

An observational study of Aortic Stenosis and Heart Failure, run by Aalborg University Hospital at 1 site in Denmark.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This observational cohort study investigates whether hemodynamic improvements following transcatheter aortic valve implantation (TAVI) are associated with improvements in patient-reported quality of life among patients in Western Denmark. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Aortic Stenosis, Heart Failure, Angina Pectoris
How many people
200 participants
Where
1 siteDenmark
Study dates
26 Aug 2026to 1 Jan 2029
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study population consists of adult patients undergoing transcatheter aortic valve implantation in Western Denmark. Patients will be included prospectively and followed from baseline assessment before TAVI to clinical follow-up after the procedure. Patient-reported health status will be assessed using the Kansas City Cardiomyopathy Questionnaire and combined with clinical, echocardiographic, anatomical, and procedural data obtained from patient records.

Who may be able to join

  • Age ≥18 years
  • Undergoing transcatheter aortic valve implantation (TAVI)
  • TAVI performed within the study recruitment period
  • Available baseline KCCQ assessment
  • Able to participate in follow-up assessment

Who cannot join

  • Severe cognitive impairment preventing completion of the KCCQ
  • Language barrier preventing completion of the KCCQ
  • Severe illness or clinical condition preventing participation in follow-up

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Department of Cardiology Aalborg University Hospital

    Gistrup, 9260

Other trials in Denmark

About this study

This observational cohort study investigates whether hemodynamic improvements following transcatheter aortic valve implantation (TAVI) are associated with improvements in patient-reported quality of life among patients in Western Denmark.

Quality of life will be assessed using the Kansas City Cardiomyopathy Questionnaire before TAVI and at follow-up. Changes in quality of life will be evaluated in relation to changes in mean transvalvular gradient, left ventricular ejection fraction, and New York Heart Association functional class. Clinical data will be obtained from patient records.

Read more

Secondary analyses will explore whether patient characteristics, comorbidities, anatomical factors, and procedural characteristics are associated with quality-of-life improvement following TAVI.

The study aims to improve understanding of the relationship between objective treatment outcomes and patients' perceived health status after TAVI.

Read the detailed description

Transcatheter aortic valve implantation (TAVI) results in substantial hemodynamic improvement in patients with severe aortic stenosis, including reduction in transvalvular pressure gradient and left ventricular afterload. However, objective improvements in valve hemodynamic may not necessarily correspond to improvements in patients' perceived health status and quality of life.

This observational cohort study will examine the relationship between changes in patient-reported health status and changes in objective and functional clinical parameters following TAVI. Patient-reported health status will be assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ) used as the primary patient-reported outcome measure.

Changes in KCCQ from baseline to follow-up will be evaluated in relation to changes in mean transvalvular gradient and left ventricular ejection fraction as well as changes in New York Heart Association functional class.

Secondary analyses will investigate factors potentially associated with variation in quality-of-life improvement after TAVI. These include demographic and clinical characteristics such as age, sex, weight, type 2 diabetes mellitus, ischemic heart disease, hypertension, atrial fibrillation, and chronic kidney disease. Anatomical and procedural characteristics, including aortic annulus size, transcatheter valve size, pre- and post-dilatation, and procedural complications, will also be evaluated.

Particular attention will be given to whether sex and anatomical characteristics are associated with differences in the relationship between hemodynamic improvement and patient-reported outcomes.

The study combines prospectively collected KCCQ data with clinical, echocardiographic, anatomical, and procedural information obtained from patient records. By examining patient-reported outcomes alongside conventional measures of treatment response, the study seeks to characterize potential discordance between objective improvement following TAVI and improvement experienced by the patient.

Medical subject headings
Aortic Valve Stenosis, Heart Failure, Angina Pectoris

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Kansas City Cardiomyopathy Questionnaire

    Change in patient-reported health status from baseline to follow-up after TAVI, assessed using the Kansas City Cardiomyopathy Questionnaire. Scores range from 0 to 100, with higher scores indicating better health status. The outcome will be calculated as the difference between follow-up and baseline KCCQ scores.

    Measured: Baseline (before TAVI) to 1-3 months after TAVI

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Sep 2026
  2. Study start26 Aug 2026
  3. Primary completion1 Sep 2028 (estimated)
  4. Study completion1 Jan 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07798713
Sponsor's protocol ID
126656
Acronym
TAVI-QoL
Status last verified
Aug 2026
First submitted
28 Aug 2026
Last updated
1 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Al-Azizi, K., Abo Hajar, M. B., Pickering, T., Moubarak, G., Dorton, C. W., McCullough, K. A., Ladner, J., Elias, M., Parro, C., McCoy, S. L., Saeed, U., Ma, T.-W., Hale, S., Gupta, S., Harrington, K. B., Schaffer, J. M., Mohiuddin, A., Brinkman, W. T., Alsaid, A., … Mack, M. J. (2026). Impact of Measured and Predicted Patient-Prosthesis Mismatch on Quality of Life Following Transcatheter Aortic Valve Implantation. Structural Heart, 10(1). https://doi.org/10.1016/j.shj.2025.100759 Arnold, S. V, Spertus, J. A., Vemulapalli, S., Li, Z., Matsouaka, R. A., Baron, S. J., Vora, A. N., Mack, M. J., Reynolds, M. R., Rumsfeld, J. S., & Cohen, D. J. (2017). Quality-of-life outcomes after transcatheter aortic valve replacement in an unselected population: A report from the STS/ACC transcatheter valve therapy registry. JAMA Cardiology, 2(4), 409-416. https://doi.org/10.1001/jamacardio.2016.5302 Cabrucci, F., Baudo, M., Yamashita, Y., Dokollari, A., Sicouri, S., & Ramlawi, B. (2024). Short and Long-Term Outcomes of Transcatheter Aortic Valve Implantation in the Small Aortic Annulus: A Systematic Literature Review. In Journal of Personalized Medicine (Vol. 14, Number 9). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/jpm14090937 Capodanno, D., Petronio, A. S., Prendergast, B., Eltchaninoff, H., Vahanian, A., Modine, T., Lancellotti, P., Sondergaard, L., Ludman, P. F., Tamburino, C., Piazza, N., Hancock, J., Mehilli, J., Byrne, R. A., Baumbach, A., Kappetein, A. P., Windecker, S., Bax, J., & Haude, M. (2017). Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: A consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 38(45), 3382-3390. https://doi.org/1

Questions about this trial

What is this clinical trial studying?

An observational study of Aortic Stenosis and Heart Failure, run by Aalborg University Hospital at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 1 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Kansas City Cardiomyopathy Questionnaire (time frame: Baseline (before TAVI) to 1-3 months after TAVI). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07798713, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in